Yahoo · Dec 2, 2025
Here's Why We're A Bit Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
GB
NASDAQ · GBIO
Generation Bio Co.
Healthcare · Biotechnology
$5.34
Up+$0.00 (+0.00%)
Updated Oct 9, 2026, 6:10 AM
SID Score
4.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 36.79M
- P/E ratio
- -0.51
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 551.92K
- Avg. volume
- 59.35K
Price performance · GBIO
GBIO price history
1M range · 0 trading sessions · Daily adjusted prices
GBIO does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest GBIO news
The latest Smart Investors Daily articles mentioning GBIO.
Stock researchCompany · Overview
Company
Market Activity
Research & News
GBIO research
Overview
Company profile and research snapshot.
Company profile
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $30.94
- Implied upside
- —
- Analysts
- 11
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 16, 2025 | Jefferies | Hold | — |
| Dec 16, 2025 | Wedbush | Outperform | — |
| Aug 18, 2025 | Canaccord Genuity | Buy | — |
| Aug 13, 2025 | Needham | Buy | — |
| Aug 13, 2025 | Wedbush | Neutral | — |
News briefing
No generated briefing is available yet.
globenewswire.com · Nov 5, 2025
Generation Bio Announces Third Quarter 2025 Financial Results
CAMBRIDGE, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company, today reported third quarter financial results.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
